Technology holds personalised cancer vaccine breakthrough

Technology holds personalised cancer vaccine breakthrough
The attack of a tumour cell made by white blood cells of the patient (lymphocytes) generated by cancer vaccines. Credit: University of Queensland

University of Queensland researchers have developed a vaccine delivery technology that enables treatment to be tailored precisely for different cancers.

UQ's Professor Ranjeny Thomas said the technology had the potential to improve the precision of cancer immunotherapy, leading to better cancer outcomes and reduce harmful side-effects.

"Flexible cancer vaccines are a long-sought treatment strategy in cancer immunotherapy," Professor Thomas said.

"Cancer vaccines represent a precision cancer treatment strategy which stimulates the immune system to attack without affecting other cells in the body.

"While a new class of immunotherapy drugs, called checkpoint inhibitors, has promising results in previously untreatable cancers, they are only effective in a limited proportion of cases, and may have inflammatory side-effects.

"Current cancer vaccines have limited flexibility and effectiveness."

The solution, tailored NanoEmulsion technology, results from a new approach to cancer vaccination.

"NanoEmulsions are tiny carrier packages that encapsulate proteins made only by cancer cells," Professor Thomas said.

"They are designed to target specific immune cells, which educate the immune system about cancer proteins."

UQ researcher Professor Riccardo Dolcetti said the process accelerated a precise immune attack on .

"The versatility and efficacy of the new NanoEmulsion-based vaccines in mice are particularly promising building blocks to tailor vaccines to individual patients and improve personalised in the future," he said.

The paper has been published in The Journal of Clinical Investigation.


Explore further

A combination of cancer immunotherapies could save more lives

More information: Bijun Zeng et al. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy, Journal of Clinical Investigation (2018). DOI: 10.1172/JCI96791
Citation: Technology holds personalised cancer vaccine breakthrough (2018, April 10) retrieved 20 May 2019 from https://medicalxpress.com/news/2018-04-technology-personalised-cancer-vaccine-breakthrough.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
23 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more